The chart is not accessible to screen readers. Please switch to the table view to access the data.
Advertisement
Advertisement
Greenhouse gas emission intensity of Novartis, Sanofi, and AstraZeneca in 2024, by scope (in metric tons of COâ‚‚ equivalent per million USD revenue)
Greenhouse gas emission intensity of Novartis, Sanofi a AstraZeneca in 2024, by scope
In 2024, AstraZeneca reported the highest greenhouse gas emission intensity among the three pharmaceutical companies, with roughly *** metric tons of CO₂e per million U.S. dollars in revenue from Scope 3, compared to around ** metric tons per million USD at Novartis and ** metric tons per million USD at Sanofi. Scope 1 and Scope 2 emissions were comparatively small for all three companies, with Sanofi reporting the highest Scope 1 and 2 emissions combined among the three companies in 2024 at over metric tons of CO₂e per million USD revenue.
Log in or register to access precise data.
* For commercial use only
Basic Account
For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
- Free Statistics
Based on your interests
Starter Account
For single users
$199 USD
per month, billed annually
1
- Free Statistics
- Premium Statistics
The statistic on this page is a Premium Statistic and is included in this account.
Professional Account
For teams of up to 99 users
Talk to sales for pricing
- Free + Premium Statistics
- Reports
- Market ÌÇÐÄÆƽâ°æ
1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.
Other statistics that may interest you Statistics on
About the industry
10
- Premium Statistic GHG emissions of Roche, Sanofi, and AstraZeneca in 2024, by scope
- Basic Statistic Preferred pharma companies by Americans for drug purchase 2017
- Basic Statistic Americans' preferred pharma companies for drug purchase, by gender 2017
- Premium Statistic Global pharmaceutical greenhouse gas footprint changes by effect and region 1995-2019
- Basic Statistic Top known pharma companies by Americans 2017
- Premium Statistic Global GHG footprint growth in pharma and health industry 1995-2019
- Premium Statistic Benefits among biopharma sustainability leaders and late adopters 2024
- Premium Statistic Sales revenue Sanofi S.r.l. in Italy 2020-2022
- Premium Statistic Sales revenue Novartis Farma S.p.A in Italy 2020-2022
- Premium Statistic Benefits due to sustainability initiatives among biopharma companies 2024
About the region
10
- Premium Statistic Slowdowns due to poor sustainability progress among biopharma companies 2024
- Premium Statistic Statements on sustainability issues among biopharma companies 2024
- Premium Statistic Technologies important for biopharma sustainability targets 2024
- Premium Statistic Global GHG emission intensity by pharma and health industry
- Premium Statistic Global biotechnology market share by region 2012
- Premium Statistic Percentage return on R&D among large cap biopharma companies 2010-2020
- Premium Statistic Employee distribution of Bracco in 2023, by role and gender
- Premium Statistic Employee distribution at Bracco in 2023, by geographic area
- Premium Statistic Employees joining Bracco in 2023, by age
- Premium Statistic Employee number at Bracco in 2023, by type of contract
Selected statistics
10
- Premium Statistic GHG reduction targets of leading pharma companies by 2030 and 2045, by scope
- Premium Statistic Revenue of top pharma and biotech companies from France 2025
- Premium Statistic Change in U.S. list and net drug prices 2024 by manufacturer
- Premium Statistic Market cap of top pharma and biotech companies from France 2025
- Premium Statistic Revenue of top pharmaceutical companies in France 2023
- Premium Statistic World pharmaceutical market distribution by submarket 2014-2025
- Premium Statistic Novo Nordisk net profit 2009-2025
- Basic Statistic Number of pharmaceutical preparation enterprises in Norway 2016-2023
- Basic Statistic Number of clinical trial starts in Denmark 2018-2023
- Premium Statistic Clinical trials in Denmark by therapeutic area 2018-2023
Other regions
10
- Premium Statistic Change in list and net drug prices select manufacturers U.S. 2017-2022
- Basic Statistic Proactive patients in reviewing select health information and issues 2013
- Basic Statistic Satisfaction or desire for received pharmaceutical services in the U.S. 2013
- Basic Statistic Top five services from pharma companies for U.S. patients 2013
- Premium Statistic Revenues of the top 20 pharmaceutical companies in France 2018
- Basic Statistic Reduction from list price of pharmaceutical products by manufacturer U.S. 2022
- Premium Statistic Novartis: ad spend in the U.S. 2012-2019
- Basic Statistic Forecast major categories of U.S. healthcare expenditures 2015-2020
- Basic Statistic Expected consequences of moving US pharma manufacturing to the US, by gender
- Basic Statistic Americans on US pharma quality compared to foreign pharma 2017, by gender
Related statistics
10
- Premium Statistic Italy: perception of pharmaceutical companies 2018, by brand
- Premium Statistic Operating profit Celltrion 2017-2024
- Premium Statistic Sales revenue Eli Lilly Italia S.p.A. in Italy 2020-2022
- Premium Statistic Sales revenue AbbVie S.r.l. in Italy 2020-2022
- Premium Statistic Sales revenue Yuhan 2023, by sector
- Premium Statistic Market share of Celltrion's Truxima in Europe Q2 2017-Q2 2018
- Premium Statistic Advertising and promotion expenses of Yunnan Baiyao Group 2017-2022
- Premium Statistic Revenue of leading hundred pharmaceutical products by region 2012
- Premium Statistic Merck & Co. - costs of marketing and administration 2009-2017
- Premium Statistic Operating income Yuhan 2015-2023
Further Content: You might find this interesting as well
* For commercial use only
Basic Account
For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
- Free Statistics
Based on your interests
Starter Account
For single users
$199 USD
per month, billed annually
1
- Free Statistics
- Premium Statistics
The statistic on this page is a Premium Statistic and is included in this account.
Professional Account
For teams of up to 99 users
Talk to sales for pricing
- Free + Premium Statistics
- Reports
- Market ÌÇÐÄÆƽâ°æ
1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.
Various sources (druganddeviceworld.com). (April 21, 2025). Greenhouse gas emission intensity of Novartis, Sanofi, and AstraZeneca in 2024, by scope (in metric tons of COâ‚‚ equivalent per million USD revenue) [Graph]. In ÌÇÐÄÆƽâ°æ. Retrieved August 02, 2026, from /statistics/1624057/ghg-emission-intensity-of-novartis-sanofi-and-astrazeneca-by-scope/
Various sources (druganddeviceworld.com). "Greenhouse gas emission intensity of Novartis, Sanofi, and AstraZeneca in 2024, by scope (in metric tons of COâ‚‚ equivalent per million USD revenue)." Chart. April 21, 2025. ÌÇÐÄÆƽâ°æ. Accessed August 02, 2026. /statistics/1624057/ghg-emission-intensity-of-novartis-sanofi-and-astrazeneca-by-scope/
Various sources (druganddeviceworld.com). (2025). Greenhouse gas emission intensity of Novartis, Sanofi, and AstraZeneca in 2024, by scope (in metric tons of COâ‚‚ equivalent per million USD revenue). ÌÇÐÄÆƽâ°æ. ÌÇÐÄÆƽâ°æ Inc.. Accessed: August 02, 2026. /statistics/1624057/ghg-emission-intensity-of-novartis-sanofi-and-astrazeneca-by-scope/
Various sources (druganddeviceworld.com). "Greenhouse Gas Emission Intensity of Novartis, Sanofi, and Astrazeneca in 2024, by Scope (in Metric Tons of Coâ‚‚ Equivalent per Million Usd Revenue)." ÌÇÐÄÆƽâ°æ, ÌÇÐÄÆƽâ°æ Inc., 21 Apr 2025, /statistics/1624057/ghg-emission-intensity-of-novartis-sanofi-and-astrazeneca-by-scope/
Various sources (druganddeviceworld.com), Greenhouse gas emission intensity of Novartis, Sanofi, and AstraZeneca in 2024, by scope (in metric tons of COâ‚‚ equivalent per million USD revenue) ÌÇÐÄÆƽâ°æ, /statistics/1624057/ghg-emission-intensity-of-novartis-sanofi-and-astrazeneca-by-scope/ (last visited August 02, 2026)
Greenhouse gas emission intensity of Novartis, Sanofi, and AstraZeneca in 2024, by scope (in metric tons of COâ‚‚ equivalent per million USD revenue) [Graph], Various sources (druganddeviceworld.com), April 21, 2025. [Online]. Available: /statistics/1624057/ghg-emission-intensity-of-novartis-sanofi-and-astrazeneca-by-scope/
Advertisement